Headquartered in Indianapolis, IN Fiscal year ends December NYSE: ELAN elanco.com
Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company dedicated to developing, manufacturing, and marketing products and services to prevent and treat disease in both farm animals and pets. With more than 70 years of animal health heritage, the company serves farmers, pet owners, and veterinarians through a diversified portfolio spanning parasiticides, dermatology treatments, vaccines, and nutritional health products. Its business is organized into two primary segments: Pet Health, which includes products like Zenrelia (a JAK inhibitor for canine dermatitis), Credelio Quattro (a broad-spectrum parasiticide), Befrena, the Advantage Family, and Seresto; and Farm Animal, which covers cattle, poultry, and swine products including ruminant health innovations. The company operates a diverse go-to-market model across multiple geographies and distribution channels, and pursues an Innovation Portfolio Productivity (IPP) strategy aimed at driving revenue growth through new product launches, lifecycle management, and geographic expansion while simultaneously expanding margins through its Elanco Ascend productivity initiative. Updated
One of Wall Street’s top firms just gave a thumbs-up to Zoetis (NYSE:ZTS | ZTS Price Prediction) stock. Citi initiated coverage with a Buy rating and a $145 price target, naming it…
The steep increase in pet healthcare costs have doubled over the past five years, according to NPR. There are a number of reasons for this trend, but the overall numbers are large,…
Friday's top analyst upgrades and downgrades included IBM, Palantir, PayPal and Snowflake.
Friday’s top analyst upgrades and downgrades included Analog Devices, Bath & Body Works, Cisco Systems, Elanco Animal Health, Exxon Mobil, Marvell Technology, MGIC Investment, Nvidia, Snowflake, Target, TJX Companies and Zoom Video…
Wednesday’s top analyst upgrades and downgrades included Apple, Carvana, Elanco Animal Health, Gilead Sciences, Home Depot, Park Hotels & Resorts, Shoals Technologies, SNDL, SITE Centers and UDR.
Wednesday’s top analyst upgrades and downgrades included Alliance Data, AvalonBay, Boston Properties, Bruker, Camden Properties and CBRE.
Tuesday's top analyst upgrades and downgrades included Activision Blizzard, Coinbase, Devon Energy, DuPont, Grubhub, Nike, Shopify, Tilray and Wynn Resorts.
Thursday's top analyst upgrades and downgrades included BioMarin Pharmaceuticals, Checkpoint Software Technologies, Cinemark, Fortinet, Palo Alto Networks, Regeneron Pharmaceuticals, Shake Shack, Ventas and Zscaler.
Tuesday's top analyst upgrades and downgrades included Best Buy, CarMax, Elanco Animal Health, General Motors, Home Depot, Intercontinental Exchange, JD.com, McDonald's, Procter & Gamble and Vonage.
Thursday's top analyst upgrades and downgrades included Charter Communications, Cisco Systems, Deere, FedEx, Lyft, Micron Technology, Nvidia, Occidental Petroleum, Ping Identity and Voya Financial.
Thursday's top analyst upgrades, downgrades and initiations included Citigroup, CommScope, CVS Health, CyberArk, Emerson Electric, Match, Mylan, Qualcomm, Roku, Square, Twitter and Vonage.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company dedicated to developing, manufacturing, and marketing products and services to prevent and treat disease in both farm animals and pets.
24/7 Wall St.'s 12-month price target for ELAN is $33.20, rated Buy. The Wall Street consensus target is $31.00. ELAN price prediction →
